BioCentury
ARTICLE | Top Story

Novartis gets full rights to ofatumumab from GSK

August 22, 2015 2:01 AM UTC

Novartis AG (NYSE:NVS; SIX:NOVN) will acquire rights to ofatumumab in all non-oncology indications from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). The human mAb against CD20 is in development to treat relapsing-remitting multiple sclerosis.

Novartis already markets ofatumumab as Arzerra to treat chronic lymphocytic leukemia (CLL). It had acquired rights to ofatumumab in oncology indications from GSK in an asset swap that closed in March (see BioCentury, April 28, 2014). ...